



4E Therapeutics

Delivering innovative medicines for pain

4etherapeutics.com | [Craig Benson](mailto:cbenson@4etherapeutics.com) | cbenson@4etherapeutics.com | 512-626-2770

COMPANY OVERVIEW

4E Therapeutics, founded in Austin, TX in 2019, is developing small molecule MNK inhibitors for the treatment of neuropathic pain, osteoarthritis, low back pain and migraine. 4E compounds selectively target MNK in the periphery to interrupt a key pathway involved in pain signaling. Our drug candidates are peripherally restricted and free of CNS side effects.

4ET1103 is our lead asset for neuropathic pain; the candidate has completed IND-enabling studies and will start a phase 1 clinical trial in 2024. 4ET1103 is on track to become a first-in-class treatment for neuropathic pain.

4ET2124 is our clinical candidate being developed for the treatment of migraine. 4ET2124 has completed preliminary *in vitro* safety studies and is ready to begin IND-enabling studies.

MARKET & COMMERCIALIZATION STRATEGY

Over 20M Americans suffer from neuropathic pain. We see a \$10B annual market revenue opportunity for a novel neuropathic pain therapeutic that excludes side effects associated with opioids.

TECHNICAL & COMPETITIVE ADVANTAGE

Mitogen-activated protein kinase interacting kinase (MNK) regulates changes in gene expression critical for pain and inflammation. Inhibiting MNK interrupts pathways involved in neuropathic pain and migraine—all independent of the opioid pathway. 4E compounds are efficacious in both rodent pain models and human DRG neurons. 4E drug candidates have excellent safety profiles and lack CNS side effects, offering a significant advantage over standard of care medications.

REGULATORY STRATEGY & INTELLECTUAL PROPERTY

4E has an extensive IP portfolio covering 4ET1103, 4ET2124 and related molecules. A prior art search and analysis verifying strong patent position for clinical candidates has been provided by patent counsel.

KEY MILESTONES

- In vivo* tox studies of 4ET1103
- IND application for 4ET1103 to be filed Q4'23
- First-in-human phase 1 trial of 4ET1103 to start Q1'24

CAPITALIZATION HISTORY

YEAR	FUNDING TYPE	DESCRIPTION	AMOUNT
2019-23	NIH Grants	Non-dilutive SBIR funding	\$7.5M
2021-23	Private	Series A	Undisclosed

USE OF PROCEEDS

Next financing round will enable completion of phase I clinical trial with 4ET1103 & IND-enablement of 4ET2124.

MANAGEMENT TEAM

[Craig Benson](#), CEO

[Theodore "Ted" Price](#), PhD., Co-Founder, Professor at University of Texas at Dallas

[James Sahn](#), PhD., Vice President of Drug Development

[Michele Curatolo](#), MD, PhD., Chief Medical Officer

[Joseph "Joe" Price](#), JD, Co-Founder, President & Chairman